Table 6 Base case environmental burden of disease results (PAF, prevalence-based EBD [DALYs and attributable cases], and attributable health costs) of ADHD associated with exposure to pyrethroids based on the exposure-response information of Dalsager et al. (2019)
Country | PAF (95% CI) [%] | EBD (95% CI) [attributable cases] | EBD (95% CI) [attributable cases per 106 inhabitants] | EBD (95% CI) [DALYs] | EBD (95% CI) [DALYs per 106 inhabitants] | Attributable health costs (95% CI) [million EUR] | Attributable health costs per 106 inhabitants (95% CI) [million EUR] |
|---|---|---|---|---|---|---|---|
France | 26 (22–30) | 113,543 (59094–170931) | 1710 (890–2589) | 1393 (425–2455) | 21 (6–37) | 156.2 (81.3–235.1) | 2.4 (1.2–3.6) |
Iceland | 14 (5–22) | 339 (95–655) | 969 (273–1927) | 4 (1–9) | 12 (2–27) | 0.6 (0.2–1.2) | 1.7 (0.5–3.5) |
Switzerland | 17 (6–27) | 8421 (2574–15143) | 944 (282–1701) | 103 (16–204) | 12 (2–23) | 17.4 (5.3–31.3) | 2.0 (0.6–3.5) |
Germany | 10 (-4–22) | 17,801 (-5757–44894) | 209 (-67–522) | 218 (-80–613) | 3 (-1–7) | 29.6 (-9.6–74.6) | 0.3 (-0.1–0.9) |
Israel | 25 (19–30) | 21,003 (11619–31569) | 2189 (1188–3352) | 258 (60–455) | 27 (6–49) | 23.8 (13.2–35.7) | 2.5 (1.3–3.8) |